 Pre-Exposure Prophylaxis
"Pre-Exposure Prophylaxis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent.
| Descriptor ID |
D065129
|
| MeSH Number(s) |
N02.421.726.758.655 N06.850.780.680.655
|
| Concept/Terms |
Pre-Exposure Prophylaxis- Pre-Exposure Prophylaxis
- Pre Exposure Prophylaxis
- Pre-Exposure Prophylaxi
- Prophylaxi, Pre-Exposure
- Prophylaxis, Pre-Exposure
- Pre-Exposure Prophylaxis (PrEP)
- Pre Exposure Prophylaxis (PrEP)
- Pre-Exposure Prophylaxi (PrEP)
- Prophylaxi, Pre-Exposure (PrEP)
- Prophylaxis, Pre-Exposure (PrEP)
|
Below are MeSH descriptors whose meaning is more general than "Pre-Exposure Prophylaxis".
Below are MeSH descriptors whose meaning is more specific than "Pre-Exposure Prophylaxis".
This graph shows the total number of publications written about "Pre-Exposure Prophylaxis" by people in this website by year, and whether "Pre-Exposure Prophylaxis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 3 | 1 | 4 | | 2015 | 3 | 2 | 5 | | 2016 | 9 | 0 | 9 | | 2017 | 13 | 2 | 15 | | 2018 | 15 | 5 | 20 | | 2019 | 10 | 3 | 13 | | 2020 | 7 | 4 | 11 | | 2021 | 27 | 2 | 29 | | 2022 | 18 | 0 | 18 | | 2023 | 13 | 0 | 13 | | 2024 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pre-Exposure Prophylaxis" by people in Profiles.
-
Cianelli R, De Santis JP, De Oliveira GC, Castro JG, Iriarte E, Baeza MJ, Thomas SO, Villegas N, Peragallo-Montano N. Feasibility and acceptability of SEPA+PrEP: An HIV prevention intervention to increase PrEP knowledge, initiation, and persistence among cisgender heterosexual Hispanic women. PLoS One. 2024; 19(1):e0296080.
-
Chi BH, Saidi F, Graybill LA, Phanga T, Mollan KR, Amico KR, Freeborn K, Rosenberg NE, Hill LM, Hamoonga T, Richardson B, Kalua T, Phiri S, Mutale W. A Patient-Centered, Combination Intervention to Support Adherence to HIV Pre-exposure Prophylaxis During Pregnancy and Breastfeeding: A Randomized Pilot Study in Malawi. J Acquir Immune Defic Syndr. 2024 01 01; 95(1):42-51.
-
Huang Y, Zhang L, Karuna S, Andrew P, Juraska M, Weiner JA, Angier H, Morgan E, Azzam Y, Swann E, Edupuganti S, Mgodi NM, Ackerman ME, Donnell D, Gama L, Anderson PL, Koup RA, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Lemos MP. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01. Nat Commun. 2023 Nov 28; 14(1):7813.
-
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023 12; 10(12):e767-e778.
-
Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, Macdonald P, Milan G, Palanee-Phillips T, Reddy K, Tahuringana E, Muhlanga F, Nakabiito C, Bekker LG, Siziba B, Hillier SL, Baeten JM, Garcia M, Johnson S, McClure T, Levy L, Livant E, Jacobson C, Soto-Torres L, van der Straten A, Hosek S, Rooney JF, Steytler J, Bunge K, Parikh U, Hendrix C, Anderson P, Ngure K. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV. 2023 12; 10(12):e779-e789.
-
Higgins DM, Riba A, Alderton L, Wendel KA, Scanlon J, Weise J, Gibson N, Obafemi O. Evaluation of the Impact and Outcomes of a Rapid Transition to Telehealth PrEP Delivery at a Sexual Health Clinic During the COVID-19 Pandemic. Sex Transm Dis. 2023 12 01; 50(12):816-820.
-
Moore M, Stansfield S, Donnell DJ, Boily MC, Mitchell KM, Anderson PL, Delany-Moretlwe S, Bekker LG, Mgodi NM, Celum CL, Dimitrov D. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. Nat Med. 2023 Nov; 29(11):2748-2752.
-
Tandon A, Saseen JJ, Fink RM, Billups SJ. Primary Care and Infectious Disease Provider Adherence to HIV Pre-exposure Prophylaxis (PrEP) Prescribing and Monitoring Recommendations. AIDS Behav. 2024 Apr; 28(4):1270-1275.
-
Musinguzi N, Ngure K, Bukusi EA, Mugo NR, Baeten JM, Anderson PL, Haberer JE. Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya. AIDS Behav. 2023 Dec; 27(12):3961-3969.
-
Pintye J, Kinuthia J, Abuna F, Anderson PL, Dettinger JC, Gomez L, Haberer JE, Marwa MM, Ngumbau N, Omondi P, Odhiambo B, Stern J, Watoyi S, Baeten JM, John-Stewart G. HIV pre-exposure prophylaxis initiation, persistence, and adherence during pregnancy through the postpartum period. AIDS. 2023 09 01; 37(11):1725-1737.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|